Results 141 to 150 of about 72,887 (326)

From mechanism to phenotype: What fits in a basket trial

Epilepsia, EarlyView.
Kette D. Valente
wiley   +1 more source

Development and Real‐World Evaluation of a Statewide Mainstream Model of Germline Genetic Testing for BRCA1/2 and Mismatch Repair Gene Variants (Lynch Syndrome)

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This translational quality improvement study evaluated a statewide pathway for mainstream genetic testing in South Australia. Adoption of mainstream BRCA1/2 testing increased significantly, but not MMR testing. Findings highlight the need for tailored, context‐specific strategies to integrate genetic testing into routine care across diverse cancer ...
Cally A. Jennings, Kathryn Cornthwaite, Michael Osborn, Ganessan Kichenadasse, Eryn Dow   +4 more
wiley   +1 more source

Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer

Pharmacological Research
The human PARP enzyme family contains 17 members that are divided into five subfamilies, the chief one of which includes the DNA-dependent enzymes (PARP1/2/3). These enzymes participate, inter alia, in DNA repair, transcription, chromatin remodeling, and
Robert Roskoski, Jr.
doaj   +1 more source

Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Summary Acute myeloid leukaemia (AML) is an aggressive disease with poor survival and high relapse rates. Coupled with the complex mutational burden observed, there is an unmet clinical need for more targeted therapies. Epigenetic therapies have shown promise both as monotherapy and in combination strategies and specifically histone lysine demethylase,
Laura Monaghan, Roderick P. Bunschoten, Joana Bittencourt‐Silvestre, Taeju Park, Susan Gannon, Petrisor Alin Pirvan, Alex Hoose, Helen Wheadon, Robert M. J. Liskamp, Xu Huang, Heather G. Jørgensen   +10 more
wiley   +1 more source

DataSheet_1_Pharmacological Poly (ADP-Ribose) Polymerase Inhibitors Decrease Mycobacterium tuberculosis Survival in Human Macrophages.pdf

, 2021
Cassandra L. R. van Doorn (11388245), Sanne A. M. Steenbergen (11758793), Kimberley V. Walburg (8392875), Tom H. M. Ottenhoff (6906818)   +3 more
openalex   +2 more sources

Structure, function and inhibition of poly(ADP-ribose)polymerase, member 14 (PARP14) [PDF]

, 2018
Levonis, Stephan M, Schweiker, Stephanie S, Sherry, Madeleine, Tauber, Amanda   +3 more
core   +1 more source

System level network data and models attack cancer drug resistance

British Journal of Pharmacology, EarlyView.
Drug resistance is responsible for >90% of cancer related deaths. Cancer drug resistance is a system level network phenomenon covering the entire cell. Small‐scale interactomes and signalling network models of drug resistance guide directed drug development.
Márk Kerestély, Dávid Keresztes, Levente Szarka, Borbála M. Kovács, Klára Schulc, Dániel V. Veres, Peter Csermely   +6 more
wiley   +1 more source

5‐aminoisoquinolin‐1(2H)‐one, a water‐soluble poly (ADP‐ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats [PDF]

, 2006
Rosanna Di Paola, Emanuela Mazzon, Carmelo Muià, Dino Terrana, Salvatore Greco, Domenico Britti, Domenico Santori, Giacomo Oteri, Giancarlo Cordasco, Salvatore Cuzzocrea   +9 more
openalex   +1 more source

SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma [PDF]

, 2020
Rashmi Chugh, Karla V. Ballman, Lee J. Helman, Shreyaskumar Patel, Jeremy Whelan, Brigitte C. Widemann, Yao Lu, Douglas S. Hawkins, Leo Mascarenhas, John Glod, Jiuping Ji, Yiping Zhang, Denise Reinke, Sandra J. Strauss   +13 more
openalex   +1 more source

The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence

British Journal of Pharmacology, EarlyView.
Cardiac remodelling and fibrosis after myocardial infarction or during chronic diseases, such as arterial and pulmonary hypertension or diabetes mellitus, continue to be the more important prognostic factors in determining survival, and so the search for effective anti‐fibrotic interventions is an important target for research and therapy in cardiology.
Anna Krzyżewska, Marta Baranowska‐Kuczko, Hanna Kozłowska   +2 more
wiley   +1 more source